Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.5 USD | +1.21% | +11.11% | +7.30% |
Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | 400K | Sales 2025 * | 250K | Capitalization | 35.25M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -40M | EV / Sales 2024 * | 88.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 141 x |
P/E ratio 2024 * |
-2.5
x | P/E ratio 2025 * |
-2.6
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.31% |
Latest transcript on VYNE Therapeutics Inc.
1 day | +1.21% | ||
1 week | +11.11% | ||
Current month | -18.57% | ||
1 month | -15.54% | ||
3 months | +38.12% | ||
6 months | +11.36% | ||
Current year | +7.30% |
Managers | Title | Age | Since |
---|---|---|---|
David Domzalski
CEO | Chief Executive Officer | 58 | 20-02-29 |
Tyler Zeronda
DFI | Director of Finance/CFO | 38 | - |
Iain Stuart
CTO | Chief Tech/Sci/R&D Officer | 51 | 20-02-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pat LePore
BRD | Director/Board Member | 69 | 20-09-09 |
Steven Basta
BRD | Director/Board Member | 59 | 14-12-31 |
Anthony Bruno
BRD | Director/Board Member | 68 | 20-02-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.5 | +1.21% | 15,899 |
24-04-25 | 2.47 | -3.89% | 77,467 |
24-04-24 | 2.57 | +10.78% | 384,779 |
24-04-23 | 2.32 | -1.28% | 30,376 |
24-04-22 | 2.35 | +4.44% | 27,675 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.30% | 35.25M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- VYNE Stock